Compounded Bioidentical Hormones: Myths and Realities

Area of Science:

• Reproductive Endocrinology
• Pharmacology

Background:

• The Women's Health Initiative (WHI) trial yielded unexpected negative-to-neutral findings for hormone therapy.
• Compounded bioidentical hormone therapy (c-BHT) has gained significant market share.
• c-BHT bypasses standard FDA requirements for safety and efficacy evidence.

Purpose of the Study:

• To analyze the factors contributing to the success of c-BHT.
• To examine the regulatory landscape influencing c-BHT prescriptions.
• To identify strategies for promoting evidence-based menopausal hormone therapy.

Main Methods:

• Analysis of the impact of WHI trial results on hormone therapy perceptions.
• Review of the regulatory status and marketing practices of c-BHT.
• Assessment of the challenges faced by clinicians balancing patient beliefs and evidence-based medicine.

Main Results:

• The WHI trial's ambiguous results and c-BHT's regulatory advantages fueled its market success.
• Unfettered marketing contributes to c-BHT accounting for one-third of menopausal hormone prescriptions.
• Clinicians face difficulties reconciling patient preferences with evidence-based treatment guidelines.

Conclusions:

• Strategies are necessary to guide patients toward safe and effective menopausal symptom management.
• Promoting evidence-based hormone therapy is crucial for patient well-being.
• Addressing the disconnect between patient beliefs and scientific evidence is essential.